The evolution of the serotonin-dopamine antagonist concept

Journal of Clinical Psychopharmacology

Volumn 15, Issue 1, 1995, Pages 4S-10S

  Huttunen, Matti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR;

CONFERENCE PAPER; DOPAMINERGIC SYSTEM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMAN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0028870605     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199502001-00002     Document Type: Article

References (65)

1. 1. Fuller RW. Role of serotonin in therapy of depression, related disorders. J Clin Psychiatry 1991;52:52–7.
2. 2. Hoffman A. A handbook of drug and alcohol abuse. 2nd ed. New York: Oxford University Press, 1983.
3. 3. Gaddum JH. Antagonism between LSD and 5-hydroxytryptarnine. J Physiol 1953;121:15P.
4. 4. Woolley DW, Shaw E. On the relationship of serotonin to schizophrenia. BMJ 1954;2:122.
5. 5. Laborit H, Hugenard P, Alluarne R. Un nouveau stabiliseur vegetatif, le 4560 RP. Presse Méd 1952;60:206–8.
6. 6. Delay J, Deniker P. Trente-huit cas de psychoses traitée par la cure prolongée et continue due 4560 RP. Le Congrés des Al. et Neurol. de Langue Fr. In: Compte rendu du Congrés. Paris: Masson et Cie, 1952.
7. 7. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140–4.
8. 8. van Rossum JM. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160:492–4.
9. 9. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717–9.
10. 10. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481–3.
11. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116–23.
12. 12. Todrick A, Tait AC, Marshall EF. Blood platelet 5-HT levels in psychiatric patients. J Ment Sci 1960;106:884–90.
13. 13. Torre M, Vergani E, Gaira S. Livelli ematici di serotonina piatrinica in schizofrenici. Acta Neurol 1970;25:740–6.
14. 14. Garelis E, Gillin JC, Wyatt RI, Neff N. Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: a preliminary study. Am J Psychiatry 1975;132:184–6.
15. 15. Jus A, Laskowska D, Zimny S. Recherches sur le comportement de la serotonine dans le serum sanguine des schizophrenes. Ann Med Psychol 1958;116:898–913.
16. 16. Feldstein A, Hoagland H, Freeman H. Blood and urinary serotonin and 5-hydroxyindole acetic acid levels in schizophrenic patients and normal subjects. J Nerv Ment Dis 1959;129:62–8.
17. 17. Halevy A, Moos RH, Solomon EF. A relationship between blood serotonin concentration and behaviour in psychiatric patients. J Psychiatr Res 1965;3:1–10.
18. 18. DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 1981;38:647–50.
19. 19. Potkin SG, Weinberger DR, Linnoila M, Wyatt RJ. Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiatry 1983;140:21–5.
20. 20. vanPraag HM. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet 1983;2:977–8.
21. 21. Banki CM, Arato M, Papp Z, Kurez M. Biochemical markers in suicidal patients. J Affect Disord 1984;6:341–50.
22. 22. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE Jr, Goodwin FK. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am J Psychiatry 1984;141:566–9.
23. 23. Cooper SJ, Kelly CB, King DJ. 5-hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal liehaviour in schizophrenia. Lancet 1992;340:940–1.
24. 24. Aghajanian GK. Neurophysiological properties of psychotomimetics. In: Hoffineister R, Stille G, eds. Handbook of experimental pharmacology. Vol. 55. Part 2. Berlin: Springer-Verlag 1981:89–110.
25. 25. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1984;40:228–31.
26. 26. Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A. Lisuride in parkinsonism. Ann Neurol 1981;9:48–52.
27. 27. Obeso JA, Luquin MR, Martinez-Lage JM. Intravenous lisuride corrects oscillations in motor performance in Parkinson’s disease. Ann Neurol 1986;19:31–5.
28. 28. Amsler HA, Teehovi L, Barth E, Harjula K, Vinopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241–8.
29. 29. Kane JM, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group. Clozapine for the treatment of resistant schizophrenia: a double blind comparison with chlorpromazine. Arch Gèn Psychiatry 1988;45:789–96.
30. 30. Bastani B, Alphs LD, Meltzer HY. Development of the Clozaril Patient Monitoring System. Psychopharmacology 1989;99:S122–5.
31. 31. Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antispychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacological proflle. J Clin Psychiatry 1994;55(suppl 5):5–12.
32. 32. Samanin R, Garattini S. The serotonergic system in the brain and its possible functional connections with other aminergic systems. Life Sci 1979;17:1201–10.
33. 33. Costall B, Naylor RJ, Marsden CB, Pycock CJ. Serotoninergic modulation of dopamine response from the nucleus accumbens. J Pharm Pharmacol 1976;28:523–6.
34. 34. Jones DL, Morgenson GJ, Wu M. Iqjections of doparninergic, cholinergic, serotoninergic and GABAergic drugs into the nucleus accumbens: effects on locomotor activity in the rat. Neuropharmacology 1981;20:29–37.
35. 35. Marsden CD. Basal ganglia disease. Lancet 1982;2:1141–6.
36. 36. Yamamoto BK, Freed CR. Asymmetric dopamine and serotonin in nigrostriatal and limbic structures of the trained circling rat. Brain Res 1984;297:115–9.
37. 37. Nishikawa T, Scatton B. The inhibitory GABAergic influence on striatal serotonergic neurons depends on the habenulo-raphe pathways. Brain Res 1984;304:157–61.
38. 38. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263–87.
39. 39. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993;50:624–35.
40. 40. Owen RR, Gurierrez-Esteinou R, Hsiao J, Hadd K, Benhelfat C, Lawlor BA, Murphy DL, Pickar D. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993;50:636–44.
41. 41. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment responses to clozapine in schizophrenic patients. Am J Psychiatry 1993;150:1337–42.
42. 2 antagonist. Mol Pharmacol 1985;27:600–11.
43. Z receptor blocker. Drug Dev Res 1986;8:205–11.
44. 2 antagonist, on parkinsonian rest tremor. Curr Ther Res 1987;41:298–300.
45. 45. Vinaâ O, Molčan J, Nhunek K, Švestka J, Zapletálek M. Ritanserin in schizophrenic patients. Activ Nerv Super 1989;31:107–9.
46. 46. Gelders Y, Vanden Bussche G, Reyntjens A, Janssen P. Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 1986;9(suppl 4):325–7.
47. 2; antagonist. Drug Dev Res 1988;15:61–73.
48. 2/1c antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451–5.
49. 49. Wiesel F-A, Nordstrûm A-L, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994;114:31–8.
50. 2 aewin. Psychopharmacol Bull 1990;26:373–6.
51. 51. Ceulemens DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM, Janssen PM. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 1985;85:329–32.
52. 52. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Steef JC, Janssen PAJ. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.
53. 2 and D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685–93.
54. 54. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.
55. 55. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–35.
56. 56. Müller-Spahn F, the International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients. an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992;15(suppl 1):90A–1A.
57. 57. Owens DGC. Extrapyramidal side effects and tolerability of risneridone: a review. J Clin Psychiatr.y 1994;55(suppl 5):29–35.
58. 2 receptors. Psychopharmacology 1993;112(suppl):S40–54.
59. 59. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982;39:784–8.
60. 60. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
61. 61. Asberg M, Montgomery S, Perris C, Schalling DS, Sedvall G. CPRS—The comprehensive psychopathological rating scale. Acta Psvchiatr Scand 1978;271(suppl):5–27.
62. l and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:589–99.
63. 63. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199–202.
64. 123I-IBZM SPET (single photon emission tomography) study. Psychol Med 1993;23:791–7.
65. 123I-IBMZ single photon emission tomography (SPET) study. Psychopharmacology (in press).